Metabolic
Retatrutide
Triple-receptor agonist reference standard studied in incretin and metabolic signalling assays.
Also indexed as: ly3437943
Indexed literature
Original citations from PubMed and ClinicalTrials.gov matched to Retatrutide. Indexing is not a quality endorsement; registration is not a published result.
- PubMedPublished trialRetatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.
Diabetes, obesity & metabolism · 2026 Nov
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
- PubMedPublished trialRetatrutide and lipid and metabolite profiles in participants with obesity with or without type 2 diabetes.
The Journal of clinical endocrinology and metabolism · 2026 Oct 16
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
- PubMedReviewMedical treatments for obesity: what does the future have in store?
The Journal of clinical endocrinology and metabolism · 2026 Oct 16
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
- PubMedResearch publicationDo Glucagon-Like Peptide-1 Receptor Agonists Sabotage Fat Grafts?: A Scoping Review of Glucagon-Like Peptide-1 Receptor Agonist Effects on Adipocyte Biology and Implications for Autologous Fat Transfer.
Aesthetic surgery journal · 2026 Oct 15
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
- PubMedResearch publicationRetatrutide treatment in streptozotocin-induced diabetic rats: renal inflammatory cytokines, HIF‑1α expression, and histopathological injury profile.
Journal of molecular histology · 2026 Oct 15
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
- PubMedReviewGLP-1 receptor agonists and hair loss: adverse effect, epiphenomenon, or therapeutic paradox?
Acta diabetologica · 2026 Oct 14
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
- PubMedReviewThe pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medications.
Journal of diabetes and metabolic disorders · 2026 Dec
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
- PubMedPublished trialRetatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.
Lancet (London, England) · 2026 Oct 10
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
- PubMedResearch publicationRetatrutide in adults with obesity and type 2 diabetes: what have we learned from TRIUMPH-2?
Lancet (London, England) · 2026 Oct 10
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
- PubMedResearch publicationUnapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain.
JAMA · 2026 Oct 9
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
- PubMedReviewGLP-1 receptor biology and the therapeutic role of incretin-based agonists in metabolic diseases.
European journal of pharmacology · 2026 Oct 8
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
- ClinicalTrials.govRegistered trial — no results postedThe Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Updated 2026-10-08 · ACTIVE NOT RECRUITING PHASE3
A trial registration is not a published result or proof of safety or effectiveness. Registry information is submitted by study sponsors and investigators.
- ClinicalTrials.govRegistered trial — no results postedA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Updated 2026-10-08 · RECRUITING PHASE3
A trial registration is not a published result or proof of safety or effectiveness. Registry information is submitted by study sponsors and investigators.
- PubMedResearch publicationEmerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide.
BMJ case reports · 2026 Oct 7
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
- ClinicalTrials.govRegistered trial — no results postedA Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
Updated 2026-10-06 · ACTIVE NOT RECRUITING PHASE1
A trial registration is not a published result or proof of safety or effectiveness. Registry information is submitted by study sponsors and investigators.
- PubMedEvidence reviewEfficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.
Annals of internal medicine · 2026 Oct
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
- PubMedReviewGastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.
Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2026 Oct
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
- PubMedResearch publicationRetatrutide trial: Triple action jab can cause weight loss of up to 25%, results suggest.
BMJ (Clinical research ed.) · 2026 Oct 1
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
- PubMedResearch publicationSelf-Reported Adverse Effects Among Social Media Users Taking Nonapproved Retatrutide.
JAMA network open · 2026 Oct 1
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
- PubMedResearch publicationEfficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.
Diabetes, obesity & metabolism · 2026 Sep 29
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
- PubMedResearch publicationRetatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.
The New England journal of medicine · 2026 Sep 29
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
- ClinicalTrials.govRegistered trial — no results postedEffect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
Updated 2026-09-28 · ACTIVE NOT RECRUITING PHASE3
A trial registration is not a published result or proof of safety or effectiveness. Registry information is submitted by study sponsors and investigators.
- ClinicalTrials.govRegistered trial — no results postedA Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Updated 2026-09-25 · ACTIVE NOT RECRUITING PHASE3
A trial registration is not a published result or proof of safety or effectiveness. Registry information is submitted by study sponsors and investigators.
- PubMedResearch publicationFuture GLP-1 receptor co-agonists and their cardiac effects.
Naunyn-Schmiedeberg's archives of pharmacology · 2026 Sep 22
PubMed indexing does not establish study quality or product safety. Read the original publication for methods and limitations.
Materials supplied by Basic Tides are for in-vitro laboratory research only. This page contains no protocols, no dosing information and no therapeutic framing; third-party literature is indexed for reference and is not authored, endorsed or interpreted by Basic Tides.